CALCA and migraine disorder: Two (4.35%), 15.22% (n = 7), 41.30% (n = 19) and 39.13% (n = 18) of migraine patients treated with CGRP (pathway) mAbs for 12 months showed a 100%, 75% (75–99%), 50% (50–74%), and an insufficient (< 50%) reduction in MMD after 12 months of treatment, respectively.